Edition:
India

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

5.69USD
1:54am IST
Change (% chg)

$-0.16 (-2.74%)
Prev Close
$5.85
Open
$5.92
Day's High
$5.98
Day's Low
$5.63
Volume
64,947
Avg. Vol
98,287
52-wk High
$7.24
52-wk Low
$2.26

Latest Key Developments (Source: Significant Developments)

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Friday, 10 Nov 2017 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article

Chromadex appoints Kevin Farr as new CFO
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Chromadex Corp :Chromadex appoints Kevin Farr as new CFO.Chromadex Corp says ‍Chromadex expects that Thomas Varvaro will transition from Chromadex over coming months to pursue other opportunities​.  Full Article

Chromadex Q4 loss per share $0.06
Friday, 17 Mar 2017 

Chromadex Corp : Chromadex reports 2016 record revenue as ingredient sales grew 34% . Q4 loss per share $0.06 .Q4 sales rose 29 percent to $5.6 million.  Full Article

Chromadex sees Q4 revenue of about $5.6 mln
Tuesday, 14 Feb 2017 

Chromadex Corp : Chromadex expects to report record fourth quarter as revenue increased approximately 29% . Sees Q4 2016 revenue about $5.6 million .Sees FY 2016 revenue about $26.8 million.  Full Article

Chromadex- FDA issues GRAS no objection letter to Niagen
Monday, 15 Aug 2016 

Chromadex Corp : GRAS status compliments new dietary ingredient status already received for Niagen . U.S. FDA issues GRAS no objection letter for Niagen .FDA has issued a generally recognized as safe no objection letter, in response to Niagen Nicotinamide Riboside Chloride (NR) GRAS filing.  Full Article

Chromadex reports Q2 earnings per share $0.00
Friday, 12 Aug 2016 

Chromadex Corp : Chromadex reports record revenue as ingredients sales climb 83 pct compared to previous year period . Q2 earnings per share $0.00 .Q2 sales rose 45 percent to $8.8 million.  Full Article

Chromadex announces $5.25 million registered direct offering
Monday, 6 Jun 2016 

Chromadex Corp : Company agreed to sell 1.1 million shares of its common stock at a per share price of $4.70 . Chromadex announces $5.25 million registered direct offering .Proceeds from transaction will be used to pay off company's existing debt facility.  Full Article

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT